MX2022001413A - Compuesto de pirimidina-5-carboxamida. - Google Patents

Compuesto de pirimidina-5-carboxamida.

Info

Publication number
MX2022001413A
MX2022001413A MX2022001413A MX2022001413A MX2022001413A MX 2022001413 A MX2022001413 A MX 2022001413A MX 2022001413 A MX2022001413 A MX 2022001413A MX 2022001413 A MX2022001413 A MX 2022001413A MX 2022001413 A MX2022001413 A MX 2022001413A
Authority
MX
Mexico
Prior art keywords
pyrimidine
carboxamide compound
compound
formula
methods
Prior art date
Application number
MX2022001413A
Other languages
English (en)
Inventor
Plaza Gema Rueno
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2022001413A publication Critical patent/MX2022001413A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La presente invención proporciona un compuesto de la fórmula: (ver Fórmula) o una sal farmacéuticamente aceptable de este, y métodos para usar este compuesto en el tratamiento de la diabetes mellitus tipo 2.
MX2022001413A 2019-08-06 2020-07-31 Compuesto de pirimidina-5-carboxamida. MX2022001413A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382686 2019-08-06
EP19382744 2019-09-02
PCT/US2020/044394 WO2021025975A1 (en) 2019-08-06 2020-07-31 Pyrimidine-5-carboxamide compound

Publications (1)

Publication Number Publication Date
MX2022001413A true MX2022001413A (es) 2022-03-29

Family

ID=71950845

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001413A MX2022001413A (es) 2019-08-06 2020-07-31 Compuesto de pirimidina-5-carboxamida.

Country Status (13)

Country Link
US (1) US20220274933A1 (es)
EP (1) EP4010324B1 (es)
JP (1) JP7261349B2 (es)
KR (1) KR20220046564A (es)
CN (1) CN114364659A (es)
AU (1) AU2020326552B2 (es)
BR (1) BR112021026790A2 (es)
CA (1) CA3145694A1 (es)
ES (1) ES2963560T3 (es)
IL (1) IL290345A (es)
MX (1) MX2022001413A (es)
WO (1) WO2021025975A1 (es)
ZA (1) ZA202200234B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2697712C2 (ru) * 2011-04-22 2019-08-19 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
EP2782580A4 (en) * 2011-11-23 2015-10-07 Portola Pharm Inc SELECTIVE INHIBITORS OF KINASES
CA3057849A1 (en) 2017-03-30 2018-10-04 The Board Of Regents Of The University Of Texas System Quinoline derived small molecule inhibitors of nicotinamide n-methyltransferase (nnmt) and uses thereof
US20230159470A1 (en) * 2020-02-14 2023-05-25 President And Fellows Of Harvard College Inhibitors of nicotinamide n-methyltransferase, compositions and uses thereof

Also Published As

Publication number Publication date
AU2020326552A8 (en) 2022-03-31
EP4010324A1 (en) 2022-06-15
ES2963560T3 (es) 2024-03-27
BR112021026790A2 (pt) 2022-05-10
EP4010324B1 (en) 2023-09-06
US20220274933A1 (en) 2022-09-01
AU2020326552A1 (en) 2022-02-24
JP7261349B2 (ja) 2023-04-19
CN114364659A (zh) 2022-04-15
CA3145694A1 (en) 2021-02-11
AU2020326552B2 (en) 2023-05-11
JP2022543265A (ja) 2022-10-11
ZA202200234B (en) 2023-07-26
IL290345A (en) 2022-04-01
KR20220046564A (ko) 2022-04-14
WO2021025975A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
EP4302826A3 (en) Glucagon-like peptide 1 receptor agonists
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
PH12020500673A1 (en) Compounds
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX2021011606A (es) Compuestos dirigidos a prmt5.
SG11201906435SA (en) Pyrimidine compound and pharmaceutical use thereof
EA202193015A1 (ru) Ингибиторы cdk
PH12021550449A1 (en) 2,6-diamino pyridine compounds.
MX2021012105A (es) Compuestos de pirrol.
ZA202204442B (en) Salt forms of a complement component c5a receptor
PH12019550154A1 (en) Azetidine derivative
EP3935037A4 (en) USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12019501566A1 (en) Amide compounds and use thereof
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2021009717A (es) Sulfonamidas biciclicas.
ZA202205158B (en) Polypeptide having mmp2-inhibitory effect
MX2022001413A (es) Compuesto de pirimidina-5-carboxamida.
WO2018102256A8 (en) Pyrrolidinone compounds
MX2021014458A (es) Compuestos triciclicos.
MY198328A (en) Adamantylmethylamine Derivative and use Thereof as Pharmaceutical
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.